{
    "symbol": "PROF",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-09 21:02:03",
    "content": "  All forward-looking statements are based on Profound's current beliefs, assumptions, and expectations, and relate to among other things, expectations regarding the efficacy of the company's treatment technologies, results of future clinical trials, the ability to obtain coding and/or reimbursement from third party payers, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance, and future commitments. We remain on track to be able to finish enrollment in the second half of 2023, and anticipate the first readout of early data in Q4 2023. We remain on track to be able to finish enrollment in the second half of 2023, and anticipate the first readout of early data in Q4 2023. Your line is open. And so I think to answer your question -- first question, the revenue is primarily coming from the revenue installed base, and number two, I think as I said in the last call, I think you should expect at least doubling of those by end of this year or maybe sooner, because this installed base will now produce revenue, then you will see impact in Q2 also. Your line is open. Your line is open. Your line is open. Your line is open."
}